TRENTAL 400 FILM-COATED TABLET 400 mg

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

有効成分:

PENTOXIFYLLINE

から入手可能:

SANOFI-AVENTIS SINGAPORE PTE. LTD.

ATCコード:

C04AD03

投薬量:

400 mg

医薬品形態:

TABLET, FILM COATED

構図:

PENTOXIFYLLINE 400 mg

投与経路:

ORAL

処方タイプ:

Prescription Only

製:

SANOFI S.P.A.

認証ステータス:

ACTIVE

承認日:

2001-11-16

情報リーフレット

This package insert is continually updated: please read carefully
before using a new pack! 

TRENTAL 400mg 
Pentoxifylline 

[Sanofi logo] 

COMPOSITION 
Each modified-release film-coated tablet contains, as active
ingredient, 400mg pentoxifylline. 
Excipients: Hydroxyethylcellulose, povidone, talc, magnesium
stearate, hydroxypropyl 
methylcellulose, titanium dioxide, erythrosine, macrogol 8000. 

PROPERTIES 
Trental 400 improves the blood flow properties by influencing
pathologically altered red cell 
deformability, inhibiting platelet aggregation, and reducing
increased blood viscosity. 
Consequently, Trental 400 enhances the nutritive microcirculation
in areas with impaired blood 
flow. 

The important feature of Trental 400 is the continuous release of
the active ingredient resulting in 
constant absorption and longlasting blood levels. 
Improvement of symptoms of cerebrovascular disorders has been
demonstrated after 
administration of Trental 400. 
Treatment of peripheral arterial occlusive diseases (e.g. intermittent
claudication) results in an 
increase in walking distance and relief of nocturnal
calf cramps and rest pain. 

INDICATIONS 
Peripheral arterial occlusive disease and arteriovenous disorders of
an arteriosclerotic or diabetic 
nature (e.g. intermittent claudication or rest pain) and trophic
disturbances (e.g. leg ulcers and 
gangrene). 
Cerebral circulatory disorders (sequelae of cerebral
arteriosclerosis such as difficulties in 
concentration, vertigo, impairment of memory), ischaemic and
post-apoplectic states. 
Circulatory disturbances of the eye or internal ear,
associated with degenerative vascular 
processes and impaired sight or hearing. 

CONTRAINDICATIONS 
Trental 400 must not be used in patients with  
– hypersensitivity to pentoxifylline, other methylxanthines or any
of the excipients (see under 
“Composition”), 
– massive bleeding (risk of increased bleeding), 
– extensive retinal ble

製品の特徴

This package insert is continually updated: please read carefully
before using a new pack!
TRENTAL 400mg
Pentoxifylline
[Sanofi logo]
COMPOSITION
Each modified-release film-coated tablet contains, as active
ingredient, 400mg pentoxifylline.
Excipients:
Hydroxyethylcellulose,
povidone,
talc,
magnesium
stearate,
hydroxypropyl
methylcellulose, titanium dioxide, erythrosine, macrogol 8000.
PROPERTIES
Trental 400 improves the blood flow properties by influencing
pathologically altered red cell
deformability, inhibiting platelet aggregation, and reducing increased
blood viscosity.
Consequently, Trental 400 enhances the nutritive microcirculation in
areas with impaired blood
flow.
The important feature of Trental 400 is the continuous release of the
active ingredient resulting in
constant absorption and longlasting blood levels.
Improvement
of
symptoms
of
cerebrovascular
disorders
has
been
demonstrated
after
administration of Trental 400.
Treatment of peripheral arterial occlusive diseases (e.g. intermittent
claudication) results in an
increase in walking distance and relief of nocturnal calf cramps and
rest pain.
INDICATIONS
Peripheral arterial occlusive disease and arteriovenous disorders of
an arteriosclerotic or diabetic
nature (e.g. intermittent claudication or rest pain) and trophic
disturbances (e.g. leg ulcers and
gangrene).
Cerebral
circulatory
disorders
(sequelae
of
cerebral
arteriosclerosis
such
as
difficulties
in
concentration, vertigo, impairment of memory), ischaemic and
post-apoplectic states.
Circulatory disturbances of the eye or internal ear, associated
with degenerative vascular
processes and impaired sight or hearing.
CONTRAINDICATIONS
Trental 400 must not be used in patients with
– hypersensitivity to pentoxifylline, other methylxanthines or any
of the excipients (see under
“Composition”),
– massive bleeding (risk of increased bleeding),
– extensive retinal bleeding (risk of increased bleeding).
PREGNANCY AND LACTATION
Insufficient experience has been gained concerning use in pregnancy.
Th